

II INTERNATIONAL SUMMER SCHOOL

Rare disease and orphan drug registries

Day 1

15.09.2014

Epidemiological study design, data sources, variables

Yllka Kodra MD PhD

National Centre for Rare Diseases

National Institute of Health, Rome, Italy

*Organised by Istituto Superiore di Sanità
Rome (Italy), September 15-19, 2014*



HEALTH
BIAIS
RISK
DISEASE
STUDIES
POPULATION
SOURCE
CONTROL
EPIDEMIOLOGY
CASE
EFFECT
NON
MEDICINE
BETWEEN
RANDOM
SYSTEMATIC
COHORT
ERROR
ONE
MORE
CAUSAL
MEDICAL
RESEARCH
BASED
STATISTICS
HISTORY
SPECIFIC
GENERAL
EPIDEMIOLOGICAL
CAUSE
BIOLOGY
EXPOSURE
VALUITY
WORK
MANAGEMENT
POLICY
DOCTOR
RETRIEVED
WOMAN
NEWS
METHODS
STATISTICAL
MODEL
SOCIAL
EFFECTS
EVIDENCE
NON-COMMUNICABLE DISEASES
RESEARCH
FINDINGS
PREVENTION
TREATMENT
DIAGNOSIS
PROGNOSIS
MORTALITY
MORBIDITY
PREVALENCE
INCIDENCE
RISK FACTORS
PROTECTIVE FACTORS
ENVIRONMENTAL
GENETIC
LIFESTYLE
SOCIOECONOMIC
CULTURAL
PSYCHOLOGICAL
BEHAVIORAL
BIOMEDICAL
PUBLIC HEALTH
COMMUNITY
GLOBAL
INTERNATIONAL
CROSS-CULTURAL
MULTICENTRAL
MULTINATIONAL
MULTIDISCIPLINARY
INTERDISCIPLINARY
TRANSDISCIPLINARY
CONVERGENT
INTEGRATIVE
PERSONALIZED
PRECISION
DIGITAL
ARTIFICIAL INTELLIGENCE
BIG DATA
GENOMICS
PROTEOMICS
METABOLOMICS
MICRORNA
EPITOMICS
CELLULAR
MOLECULAR
SYSTEMS
BIOMIMETIC
BIODISCOVERY
BIODESIGN
BIOPROCESSING
BIOMATERIALS
BIODEVICES
BIOSIGNALS
BIOSYSTEMS
BIOTECHNOLOGY
BIOMEDICAL ENGINEERING
BIOMEDICAL SCIENCE
BIOMEDICAL RESEARCH
BIOMEDICAL EDUCATION
BIOMEDICAL CARE
BIOMEDICAL ETHICS
BIOMEDICAL LAW
BIOMEDICAL POLICY
BIOMEDICAL ECONOMICS
BIOMEDICAL SOCIETY
BIOMEDICAL HISTORY
BIOMEDICAL FUTURE

Some epidemiological concepts

- Descriptive vs Analytic
- External Validity vs internal Validity
- Outcome vs Exposure
- Prospective vs Retrospective
- Prevalence vs Incidence

Descriptive Studies

- characterize the disease distribution in relation to: person, place, time (who, where, when);
- the first stage of epidemiological study and generate hypotheses;
- useful data for health planning and to evaluate the burden of diseases but not to understand the cause of a disease;
- simple statistical analysis (descriptive analysis);
- does not include a comparison group;
- generate hypotheses;
- non longitudinal data;
- provide rapid information.


Analytic Studies

- understand the causes of a disease, risk factor/s, prognosis or treatment effect, analyse the strength of association between exposure and outcome (why and how);
- the second stage in which hypotheses generated in the descriptive phase are tested;
- useful data to understand the cause/s of a disease but not for health planning and burden of diseases;
- complex statistical analysis (inferential analysis);
- include a comparison group;
- follow-up is essential;
- don't provide rapid information.

Validity

- **Validity** refers to whether a study is able to answer accurately the questions it is intended to answer.
 - ***internal validity*** the extent to which a measurement accurately reflects what it is intended to reflect;
 - ***external validity*** the generalizability of the information to broader settings of patients, physicians, and health care settings.

Internal Vs. External Validity



Descriptive Study

- characterize the disease distribution in relation to person, place, time (who, where when)
- the first stage of epidemiological study and generate hypothesis
- useful data for health planning and burden of diseases but not to understand the cause of disease
- simple statistical analysis (descriptive analysis)
- not include a comparison group
- generate hypothesis
- non longitudinal data
- provide timely information

Analytic Study


- understand the cause/s of a disease, risk factor/s, prognosis or treatment effect, **analyse the strength of association between exposure and outcome** (why and how)
- the second stage in which hypotheses generated in the descriptive phase are tested.
- useful data to understand the cause of disease but not for health planning and burden of diseases
- Complex statistical analysis (inferential analysis)
- include a comparison group
- follow-up is essential

	Outcome Present	Outcome Absent	
exposure present	a	b	N_1
exposure absent	c	d	N_2
	N_3	N_4	N_T

- Exposure can be a risk factor (tobacco use), a prognostic factor, a diagnostic test, or a treatment.
- Outcome development of a disease or symptom (e.g. lung cancer) or curing a disease or symptom (e.g. reduction of pain).

Example

- *Does alcohol intake increase the risk of lung cancer?*




Does treatment X improve the disease prognosis?



Prospective vs Retrospective

- **Prospective:** a group of people exposed are observed to see whether they develop the outcome.
- **Retrospective:** the same methodology but follow-up retrospectively. They use data already collected for other purpose. Offer advantage in term of cost and speed of execution.


Prospective



Start-up study



Retrospective



Population study



Exposure yes




Exposure no



Disease yes



Disease no



Disease yes



Disease no


Start-up study

Prevalence vs incidence



- Prevalence: how many people (ALIVE) have this disease right now?
- Incidence: how new cases are diagnosed during the 2014?

Example



Prevalent cases at 28 february =1

Incidence cases in february are =4

Estimation of prevalence need retrospective study and the up date of vital status is essential

Estimation of incidence need propective study



Epidemiological study design

- which epidemiological study design will be the most appropriate to fulfill the purpose of the study;
- the choice of design for a particular issue will involve trade-offs between speed, cost, quality, and relevance to key policy questions.


The principle is: high quality information
at a sufficiently low cost!

Primary research


Secondary research



Randomized controlled trial



Observational study



A patient registry definition

An organized system using **observational study methods** for the collection, storage, retrieval, and use of a clearly defined set of data on identifiable individuals or a population defined by a particular disease, condition, or **exposure**, to evaluate specified **outcomes** for one or more predetermined scientific, clinical, or policy purpose(s).

Source: Gliklich, RE and Dreyer, NA., editors. AHRQ. Registries for Evaluating Patient Guide. Agency for Healthcare Research and Quality; Rockville, MD: 2014

What are observational studies?

NCBI Resources ▾ How To ▾

MeSH

MeSH ▾

observational study|

[Save search](#) [Limits](#) [Advanced](#)

[Observational Study \[Publication Type\]](#)

A clinical study in which participants may receive diagnostic, therapeutic, or other types of interventions, but the investigator does not assign participants to specific interventions (as in an interventional study).

Year introduced 2014

Observational studies are the only method where:

- a CT may be unethical
- or the condition is rare

Descriptive purpose




Cross sectional study (prevalence)
Surveillance (prevalence/incidence)

**Observational
Study**



Case-control
Cohort (retro or prospective)



Analytic purpose


Key points on OS

- **Cross sectional studies** are the best way to determine prevalence
- Are relatively quick
- Can study multiple outcomes
- Do not themselves differentiate between cause and effect or the sequence of events

- **Case-control studies** are simple to organise
- Retrospectively compare two groups
- Aim to identify predictors of an outcome
- Permit assessment of the influence of predictors on outcome via calculation of an odds ratio
- Useful for hypotheses generation
- Can only look at one outcome
- Bias is an major problem

- **In Cohort** study subjects are selected before the outcome of interest is observed
- They establish the sequence of events
- Numerous outcomes can be studied
- They are the best way to establish the incidence of a disease
- They are a good way to determine the causes of diseases
- The principal summary statistic of cohort studies is the relative risk ratio
- If prospective, they are expensive and often take a long time for sufficient outcome events to occur to produce meaningful results

Increasing
evidence strength



Registries

- Registries are the most difficult of the observational studies to organize as they require the most expensive resources to run effectively.
- A Registry is similar to a cohort study.
The difference between the two is that, in the registry, a new subject will join the study after start, whereas in a cohort study interest is restricted to those in original group.

Public health surveillance/registry

- descriptive purposes (prevalence/incidence);
- the study population must be representative of the population (high external validity (population-based));
- need a strong collaboration between public with private;
- need the backing of health authorities and this will happen when the authorities have something to gain from the registry.

Clinical registry

- Analytic purpose (cause, prognosis, treatment efficiency);
- The population coverage is not essential (non population based) and are based on selected bodies, clinical centers. The design is cohort. If the data are available a retrospective cohort design is the quickest method.

Descriptive Studies

- characterize the disease distribution in relation to: person, place, time (who, where, when);
- the first stage of epidemiological study and generate hypotheses;
- useful data for health planning and to evaluate the burden of diseases but not to understand the cause of a disease;
- simple statistical analysis (descriptive analysis);
- does not include a comparison group;
- generate hypotheses;
- non longitudinal data;
- provide rapid information.

Analytic Studies

- understand the causes of a disease, risk factor/s, prognosis or treatment effect, analyse the strength of association between exposure and outcome (why and how);
- the second stage in which hypotheses generated in the descriptive phase are tested;
- useful data to understand the cause/s of a disease but not for health planning and burden of diseases;
- complex statistical analysis (inferential analysis);
- include a comparison group;
- follow-up is essential;
- don't provide rapid information.

It is important to take familiarity with Observational Study

STROBE

- **STrengthening the Reporting of OBservational studies in Epidemiology (STROBE) Statement: Guidelines for reporting observational studies. 2007 Plos Med 4(10):e296.**

Aim: provide guidance on how to report OS

ISPOR

- **A Checklist for Retrospective Database Studies—Report of the ISPOR Task Force on Retrospective Databases. Value in Health 6 (2003) 90-7.**

Aim: evaluate the quality of published studies that use retrospective databases.

ISPOR

- **Prospective Observational Studies to assess Comparative Effectiveness: The ISPOR Good Research Practices Task Force Report. Value in Health 15 (2012) 217-230.**

Aim: provide guidance on how to design and conduct OS

ISPOR develop good research practices for Prospective Observational that focus on the effectiveness and/or comparative effectiveness of health care intervention so called **CER (Comparative Effectiveness Research)** study.

Comparative effectiveness research (CER)

- CER is defined as the:
conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, diagnose, treat and monitor health conditions in the “real word setting”
- Interventions may include medications, procedures, devices, technologies, behavioral change strategies.

Comparative effectiveness research

- CER Comparative effectiveness research are defined as the:
 - conduct and synthesis of research comparing the benefits and harms of different interventions and strategies to prevent, diagnosis, treat and monitor health conditions in “real word setting”

How efficient is a new treatment in practice

Intervention may include medications, procedures, devices, technologies, behavioral change strategies

CER and off-label treatments

- For off-label treatment, it exists the phenomenon of “clinical equipoise”;
- Clinical equipoise has been defined by Freedman B (*N Engl J Med 1987*) as the existence of “genuine uncertainty within the expert medical community about the preferred treatment”.
- When clinical equipoise exists, the most appropriate design is not a Clinical trial but a prospective observational study.

Data sources: Where can the necessary data be found?

- Primary data collected by the researcher for the purpose of the study.
- Secondary data (administrative data) are pre-existing databases originally collected for reasons other than this research. These data are used for retrospective study.

ADVANTAGES AND DISADVANTAGES OF USING PRIMARY AND SECONDARY DATA

Primary Data

Advantages

Investigator controls all aspects of the study including design, sampling techniques, data collection, and follow-up methods

All variables of interest can be measured

Disadvantages

Time consuming

Expensive

Secondary Data

Advantages

Relatively fast and inexpensive

Sample sizes tend to be large

Sample may cover a large geographic area and thus provide ability to assess national trends

Unobtrusive to subjects

Disadvantages

Data may not include all variables of interest

Maybe difficult to understand how and why data elements were collected


Melissa D.A. Carlson 2009

Example of secondary data source

Demographic and lifestyle data	Census, General Household Survey, social trends, annual reports
Morbidity data	GP morbidity statistics, communicable disease surveillance, hospital inpatient inquiry, hospital activity analysis, cancer registration
Mortality data	OPCS mortality statistics
Health services data	Immunisation data, screening levels, district and annual reports, confidential inquiry reports.
Specific databases	OPCS survey of disability, OPCS longitudinal study, abortion

Quality and quantity of data sources

- a rare condition could be identified from a large population;
- the best quality case ascertainment for rare events is possible when we focus on a limited population.



Variables (1)

- The gold rule is to keep the data sheet as short and as simple as possible.
- The content of the form (i.e., the data collected) is of course, driven by the goals:
 - public health surveillance needs relatively limited information;
 - clinical registry based on prospective cohort observational studies need more variables on risk factors and outcomes.
- Data collection is a tedious and time-consuming process, so it is important to limit metrics that are of secondary importance.
- List variables in exposure and outcome.
- Variable to uniquely identify patients (prevent duplicate records).

Patient-reported variables (2)

- Variables include patient-reported (data source patients)
- Example of patient-reported data (PROs Patient reported outcome) include health related quality of life; symptoms; complementary, and alternative medications; behavioral data (e.g., smoking and alcohol use); family history; and biological specimens.
- These data may rely on the subjective interpretation (recall bias)

Clinical variable (3)

- Variables include clinical data (data source: clinicians medical records).
- Examples of clinician data include clinical impressions, clinical diagnoses, clinical signs, differential diagnoses, laboratory results, and staging.
- The primary advantage of clinicians data is that clinicians are trained observers. Even so, the primary disadvantages are that clinicians are not necessarily accurate reporters of patient perceptions, and their responses may also be subject to recall bias. Also, the time that busy clinicians can devote to registry data collection is often limited.

Study protocol (1)

One of the most important components of research design is the creation of a study protocol, which is the researchers' blueprint to guide and govern all aspects of how a study will be conducted. A study protocol directs the execution of a study to help ensure the validity of the final study results. It also provides transparency as to how the research is conducted and improves the reproducibility and replicability of the research by others, thereby potentially increasing the credibility and validity of a study's findings.

Protocol outline (2)

1. **Purpose:** What is the key health policy question that the study is designed to answer?
2. **Background:** What is the current state of knowledge?
3. **Hypotheses:** What is the primary hypothesis? What are the secondary hypotheses (if any)?
4. **Study Design:**
 - a. Study design and rationale
 - b. Definition of population (patients, providers, sites) that will be studied (target of inference)
 - c. Definition of treatment cohorts to be compared
 - d. Definition of outcome measures to assess treatment effects
 - e. Definition and justification of control outcome (if any)
5. **Data Analysis Plan:**
 - a. Sample size justification
 - b. Primary planned analyses, secondary planned analyses
 - c. Definition of relative effectiveness measure or causal effect (average causal effect, local causal effect)
 - d. Planned approaches to deal with bias, confounding, missing data, and multiple outcomes(if secondary outcomes)
 - e. List confounders (whether collected or not)

Protocol outline (2)

6. Study Governance and Implementation:

- a. Governance and sponsorship
- b. Incentives for participation (if any)
- c. Safety reporting
- d. Informed consent and IRB approval (if required)
- e. Data processing and quality control
- f. Sample listing of data elements
- g. Plan for dissemination of results and publication planning
- h. If the study is designed to support a policy decision, explanation of decision to register study or not
- i. Anticipated timing of dissemination and publication of study results

Running successfully the registry will require expertise in Epidemiology and Biostatistics.